Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Head and Neck Squamous Cell Carcinoma Clinical Trial

Official title:

Sleep and Circadian Rhythm Study in Head and Neck Cancer Patients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05099952
• Other study ID #: I 864421
• Secondary ID: NCI-2021-09748I
• Status: Withdrawn
• Phase: N/A
• Start date: December 15, 2021
• Est. completion date: December 15, 2026

Study information

• Verified date: December 2021
• Source: Roswell Park Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This clinical trial studies the effect and underlying mechanisms of sleep and circadian rhythm factors on oral mucositis pain in head and neck cancer patients treated by chemoradiotherapy. Poor sleep may have a correlation to increased pain. A behavioral intervention, Brief Behavioral Therapy for Cancer related Insomnia, may improve patients' sleep and may also reduce oral mucositis pain.

Description:

PRIMARY OBJECTIVES:

I. To examine the effect and underlying mechanisms of sleep and circadian rhythm factors on oral mucositis pain in head and neck cancer patients treated by chemoradiotherapy.

Ia. To assess the impact of chemo-radiotherapy (CRT) on the onset and duration of sleep disturbance in head and neck carcinoma (HNC) patients, and identify factors that trigger or aggravate sleep disturbance.

Ib. To examine the effect of the association between sleep and CRT-induced oral mucositis (OM) pain.

SECONDARY OBJECTIVE:

I. To examine the pathways by which sleep disturbance may aggravate radiation-induced OM pain.

OUTLINE:

OBSERVATIONAL STUDY: Patients wear actigraphy watch and complete sleep log at baseline (over the weekend prior to first day of CRT), and weeks 1, 3, and 6 during treatment. Patients also undergo collection of cheek cell samples and may undergo collection of blood samples at weeks 1, 3 and 6 during treatment. Patients' medical records are also reviewed.

INTERVENTION STUDY: Patients are randomized to 1 of 2 arms.

ARM I: Patients participate in BBT-CI over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.

ARM II: Patients meet with therapist over 60 minutes for 2 sessions and phone calls over 15 minutes once weekly for 4 weeks.

After completion of study, patients are followed up at 1, 3, 6, and 12 months.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 15, 2026
• Est. primary completion date: December 15, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with histologically confirmed head and neck squamous cell carcinoma who have a CRT treatment scheduled at Roswell Park

• Age >= 18 years of age

• Able to read, comprehend and speak the English language

• Willing to wear a wristwatch (actiwatch) and complete the sleep log to monitor sleep and activity for three weeks (Week 1, 3, and 6) during CRT

• Willing to wear the ApneaLink Air at-home sleep monitor for one night at baseline (pre-CRT)

• Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure

• Willing to provide biospecimen samples (saliva, cheek cells, and blood) twice during CRT (week 1 and week 4) and optional for week 6

• ADDITIONAL INTERVENTIONAL STUDY CRITERIA

• Insomnia Severity Index (ISI) total score >= 7

• Willing to complete a course of Brief Behavioral Therapy for Insomnia (BBT-CI) during the treatment weeks

Exclusion Criteria:

• Participant does not meet the overall Inclusion Criteria for this study

• Patients who developed severe oral mucositis with World Health Organization Scale III or above with ulcers on the cheeks

• ADDITIONAL INTERVENTION STUDY (BBT-CI): Currently receiving treatment for insomnia or other sleep disorders

• ADDITIONAL INTERVENTION STUDY (BBT-CI): History of severe mental illness

• ADDITIONAL INTERVENTION STUDY (BBT-CI): Attending behavioral intervention programs for smoking cessation or other substance use disorders

• ADDITIONAL INTERVENTION STUDY (BBT-CI): Shift workers or persons with a known sleep disorder affecting regular sleep phase initiation (e.g. sleep onset outside the 9 pm- 12 am hours)

• Unwilling or unable to follow protocol requirements

• Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for study participation

• Cognitively impaired adults/adults with impaired decision-making capacity, individuals who are not yet adults (infants, children, and teenagers), pregnant women, and prisoners are all excluded from this study

Related Conditions & MeSH terms

• Head and Neck Neoplasms
• Head and Neck Squamous Cell Carcinoma
• Squamous Cell Carcinoma of Head and Neck

Intervention

Procedure:
• Biospecimen Collection
Undergo collection of cheek cell and blood samples

Other:
• Counseling
Meet with therapist
• Educational Intervention
Participate in BBT-CI sessions
• Electronic Health Record Review
Medical records are reviewed
• Medical Device Usage and Evaluation
Wear actigraphy watch
• Questionnaire Administration
Ancillary studies

Locations

Country	Name	City	State
United States	Roswell Park Cancer Institute	Buffalo	New York

Sponsors (1)

Lead Sponsor	Collaborator
Roswell Park Cancer Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Development of oral mucositis (OM)	OM is assessed weekly during treatment by clinical exam and patient reported Oral Mucositis Weekly Questionnaire-Head and Neck Cancer (OMWQ-HN).	Up to 1 year
Primary	Self-reported oral mucositis pain	OM pain is assessed using a visual analog scale that rates patients' overall mouth and throat soreness, on a scale of 0-10, weekly during CRT and after chemoradiotherapy (CRT) up to one year at follow up visits.	Up to 1 year
Primary	Insomnia Severity Index (ISI)	A brief questionnaire where the total responses are added up with higher scores indicating more acute symptoms of insomnia.	Up to 1 year
Primary	Sleep Efficiency	Will be measured by using a non-invasive wrist actigraphy monitor.	Up to 1 year
Primary	Sleep Disturbance	Sleep diaries will assess sleep and wake time	Up to 1 year
Secondary	Systemic inflammatory markers will include IL-6, IL1b and TNF.		Up to 1 year
Secondary	Correlation of sleep measurement with total opioid use	Opioids are carefully prescribed as standard of care during CRT according to the severity of pain. Total opioid use, summarized by morphine milligram equivalents, will therefore also be assessed as a surrogate for overall pain severity.	Up to 1 year